Table of Contents
Overview:
Hydrocodone bitartrate is a commonly used drug for acute and chronic pain in the United States. The United States is the main consumer of Hydrocodone bitartrate, consuming 99 percent of the global supply for 4.4 percent of the population worldwide. Since it is easily available and shows abuse patterns, Hydrocodone bitartrate can be used for opioid-related abuse and misuse. The FDA first approved it on November 20, 2014.In this comprehensive article, we will learn about the details of Hydrocodone bitartrate, exploring its therapeutic uses, mechanism of action, dosage and administration, potential side effects, and the broader context of opioid use in pain management.
Dosage:
Initial Dosage:
Initiate therapy for Hydrocodone bitartrate extended-release capsules by starting with one 10 mg (milligrams) capsule every 12 hours. The dosage is adjusted based on the severity of the pain and the patient’s response. However, the tolerance to Hydrocodone bitartrate can be observed with continued use.
Precautions:
-
Patient Assessment: Healthcare professionals should conduct a proper assessment of the patient's medical history, paying special attention to respiratory conditions, a history of substance abuse, and the use of other medications that may interact with Hydrocodone bitartrate.
-
Risk of Dependency and Addiction: Opioids have a risk of dependence and addiction. Patients must be informed of these risks, and healthcare providers should monitor for signs of misuse or dependency during treatment.
-
Pregnancy and Breastfeeding: Hydrocodone bitartrate use during pregnancy and breastfeeding requires careful attention. The risks to the developing fetus or nursing infant should be calculated against the benefits of pain management. However, alternative medications can be explored when possible.
-
Withdrawal Management: Abrupt discontinuation of Hydrocodone bitartrate can cause withdrawal symptoms. A gradual tapering approach is generally used under the guidance of a healthcare professional to decrease the risk of withdrawal reactions.
For Patients:
Why Is Hydrocodone Bitartrate Prescribed?
Hydrocodone bitartrate is regarded as a prominent drug for pain management, particularly used to relieve moderate to severe pain. This opioid analgesic has found its place in medical practice due to its potent pain-relieving properties.
What Are the Side Effects of Hydrocodone Bitartrate?
1. Gastrointestinal Effects: Common side effects of Hydrocodone bitartrate, particularly during the initial stages of treatment, include:
-
Nausea.
-
Vomiting.
-
Managing these effects may involve taking the medication with food or adjusting the dosage.
2. Central Nervous System Effects: Frequent side effects of opioids, including Hydrocodone bitartrate, include:
-
Drowsiness.
-
Dizziness.
-
Patients are often cautioned against engaging in tasks that require mental alertness.
3. Constipation: Opioids have a well-known propensity to slow down bowel movements, leading to constipation. Patients should maintain adequate hydration and incorporate dietary fiber to mitigate this common side effect.
4. Respiratory Depression: Perhaps the most serious side effect associated with opioids, including Hydrocodone bitartrate, is respiratory depression. In high doses or when misused, Hydrocodone bitartrate can significantly slow down breathing, posing a potentially life-threatening risk.
Overdose:
Acute overdosage with Hydrocodone bitartrate extended-release capsules can lead to the following:
-
Respiratory depression.
-
Somnolence (the state of feeling drowsy), further progressing to stupor (the state of being nearly unconscious) or coma.
-
Skeletal muscle flaccidity.
-
Cold and clammy skin.
-
Constricted pupils.
In certain cases, the following side effects might be seen:
-
Pulmonary edema.
-
Hypotension (low blood pressure).
-
Bradycardia (decreased heart rate).
-
Hypoglycemia (low blood glucose levels).
-
Partial or complete airway obstruction.
-
Marked mydriasis with hypoxia in case of an overdose.
-
Atypical snoring.
Emergency Treatment of Opioid Overdose:
Opioid overdosing is treated with Naloxone. Consult healthcare professionals about the availability of Naloxone for the emergency treatment of opioid overdose, both when starting and renewing a treatment with Hydrocodone bitartrate tablets. Inform the patients about the various ways to obtain Naloxone as permitted by the individual state and prescribing requirements or guidelines, i.e., prescription requirements, from a pharmacist directly or as part of a community program. Educate patients and caregivers about recognizing the symptoms caused by an overdose. Explain to patients and healthcare professionals that Naloxone's effects are temporary and that they must get emergency medical help immediately in all cases of known or suspected opioid overdose, even after Naloxone is administered.
Storage:
-
The risks associated with accidental ingestion, misuse, and abuse are that patients are advised to store Hydrocodone bitartrate tablets securely, away from children, and in a location inaccessible to others.
-
Inform patients that leaving Hydrocodone bitartrate tablets unsecured can have a deadly effect on others in the home.
-
The patients must be advised that when medicines are no longer needed, they must be disposed of promptly.
-
Expired, unwanted, or unused Hydrocodone bitartrate tablets must be disposed of by flushing the unused medication down the toilet if a drug take-back option is unavailable.
Addiction, Abuse, and Misuse:
The patients must be informed of the use of Hydrocodone bitartrate, as it can lead to addiction, abuse, and misuse even when taken as recommended; this can further lead to overdose and death. Patients must be strictly instructed not to share Hydrocodone bitartrate with others and to protect Hydrocodone bitartrate from theft or misuse.
Life-Threatening Respiratory Depression: The patients should be informed regarding the risk of life-threatening respiratory depression, including information that the risk is greatest when starting Hydrocodone bitartrate tablets or when the dosage is increased. However, it can occur even at recommended dosages. Educate patients and caregivers on how to understand respiratory depression and emphasize the significance of getting emergency medical help immediately in the case of a known or suspected overdose.
For Doctors:
Indications:
-
Acute Pain Management: Hydrocodone bitartrate is used primarily in short-term acute pain management. Hydrocodone bitartrate is often used for quick and efficient pain relief after surgery or from trauma.
-
Chronic Pain Conditions: In cases where persistent pain is a daily challenge, Hydrocodone bitartrate may be employed for around-the-clock pain management. Conditions such as chronic arthritis, neuropathic pain, or degenerative disorders may benefit from the sustained relief offered by Hydrocodone.
-
Combination Formulations: Hydrocodone bitartrate is usually combined with other non-opioid analgesics such as Acetaminophen or Ibuprofen in various formulations. These combinations aim to maximize pain relief while minimizing the potential side effects related to higher doses of opioids.
Contraindications:
Hydrocodone bitartrate is contraindicated in patients with:
-
Respiratory depression.
-
Acute or severe bronchial asthma.
-
Any form of gastrointestinal obstruction, including paralytic ileus.
-
Hypersensitivity to Hydrocodone bitartrate.
Dosage and Administration:
-
Formulations and Extended-Release Versions: Hydrocodone bitartrate is available in different formulations, including tablets, capsules, and liquid solutions. Extended-release formulations are designed to relieve prolonged pain and are administered every 12 hours. The specific needs and preferences of the patient determine the choice of formulation.
-
Individualized Approach: The dosage of Hydrocodone bitartrate is not a one-size-fits-all scenario. Healthcare providers carefully assess the patient's pain levels, medical history, and response to the medication to tailor the dosage accordingly. Individualized treatment plans are essential to optimize pain control and minimize risks.
Pharmacodynamics
1. Effects on the Central Nervous System:
The primary therapeutic action of Hydrocodone bitartrate is analgesia or pain relief. Hydrocodone bitartrate causes respiratory depression by direct action on brain stem respiratory centers. A reduction in the responsiveness of the respiratory centers in the brain stem causes respiratory depression.
Pinpoint pupils indicate opioid overdose; however, it is not pathognomonic, as pontine lesions of hemorrhagic or ischemic origins might show similar findings. Marked mydriasis (dilated pupils that can occur normally or in response to trauma, illness, or drugs) rather than miosis (contraction of the pupil that may be temporary or permanent, based on the cause) may be seen due to hypoxia in overdose situations.
2. Effects on the Gastrointestinal Tract and Other Smooth Muscles:
Hydrocodone bitartrate decreases motility and is associated with a high smooth muscle tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed, and propulsive contractions are reduced. Propulsive peristaltic waves in the colon are also decreased. Other opioid-induced effects lead to a decrease in biliary and pancreatic secretions and transiently elevated serum amylase.
3. Effects on the Cardiovascular System:
Hydrocodone bitartrate causes peripheral vasodilation, which might lead to orthostatic hypotension or syncope. Manifestations of histamine release or peripheral vasodilation might involve red eyes, pruritus (itching), flushing, sweating, and orthostatic hypotension.
4. Effects on the Endocrine System:
Opioids generally stop the secretion of cortisol, adrenocorticotropic hormone (ACTH), and luteinizing hormone (LH) in humans. They also stimulate growth hormone (GH) secretion, prolactin, and pancreatic secretion of insulin and glucagon.
Chronic use of opioids can affect the hypothalamic-pituitary-gonadal axis, which causes androgen deficiency that can lead to symptoms such as low libido, erectile dysfunction, impotence, amenorrhea (absence of monthly menstrual periods), or infertility.
5. Effects on the Immune System:
Opioids show various effects on components of the immune system. However, the clinical significance of these findings is still unknown. The effects of opioids are generally modestly immunosuppressive.
Pharmacokinetics
1. Absorption: After oral administration, Hydrocodone bitartrate is quickly absorbed from the gastrointestinal tract, with maximum plasma concentrations occurring within one to two hours.
2. Distribution: Hydrocodone bitartrate has a moderate degree of plasma protein binding, influencing its distribution in the bloodstream. Hydrocodone bitartrate is distributed throughout the body, including the central nervous system, liver, and other tissues.
3. Metabolism: Most Hydrocodone bitartrate undergoes hepatic metabolism, primarily through the cytochrome P450 enzyme system. The primary enzyme involved is CYP2D6. Hydrocodone bitartrate is metabolized to its active metabolite, hydromorphone, although Hydrocodone bitartrate itself also possesses opioid activity. Hydromorphone contributes to the analgesic effects of Hydrocodone bitartrate.
4. Elimination:
-
Half-life: The elimination half-life of Hydrocodone bitartrate is approximately 3.8 hours. This means it takes about 3.8 hours for half of the administered dose to be eliminated from the body.
-
Excretion: Hydrocodone bitartrate and its metabolites are primarily excreted in the urine. Approximately ten to twenty percent of the dose is excreted unchanged, while the majority is eliminated as metabolites.
Factors Affecting Pharmacokinetics:
-
Genetic Variability: Genetic polymorphisms in the CYP2D6 enzyme can result in individual variations in the metabolism of Hydrocodone bitartrate. Some individuals may be "poor metabolizers," leading to higher plasma concentrations and increased susceptibility to side effects.
-
Drug Interactions: Concurrent use of medications that inhibit or induce CYP2D6 can affect the metabolism of Hydrocodone bitartrate. Inhibitors may increase the risk of opioid toxicity, while inducers may reduce the efficacy of Hydrocodone bitartrate.
-
Renal Impairment: Although the primary route of elimination is hepatic, individuals with renal impairment may experience a longer duration of action due to decreased clearance of the drug and its metabolites.
Mechanism of Action:
-
Opioid Receptor Interaction: Hydrocodone, the active ingredient in Hydrocodone bitartrate, operates through the intricate network of opioid receptors in the central nervous system. These receptors, primarily located in the brain and spinal cord, play a pivotal role in modulating pain perception. By binding to these receptors, Hydrocodone alters the transmission of pain signals, reducing pain perception.
-
Endorphin Release: The opioid receptors targeted by Hydrocodone are part of the endorphin system, which is the body's natural pain control mechanism. Hydrocodone enhances the release of endorphins, the body's endogenous opioids, providing an additional layer of pain relief.
Clinical Trial:
A 12-week study assessed the efficacy and safety of a single-entity, once-daily extended-release hydrocodone bitartrate 20 to 120 mg tablets in opioid-naive and opioid-experienced individuals with uncontrolled moderate to severe chronic low back pain (CLBP).
The primary endpoint was pain intensity scores at week 12, determined with a mixed effect model that includes repeated measures and a pattern mixture model framework. Of 905 patients treated with extended-release Hydrocodone bitartrate tablets, 588 (65 percent) were randomly assigned to continue receiving extended-release Hydrocodone bitartrate tablets or a matched placebo.
Extended-release Hydrocodone bitartrate tablets led to significant pain reduction, greater than or equal to 30 and 50 percent improvement from screening to week 12. Hydrocodone bitartrate was typically well tolerated and proved to be an effective treatment for CLBP.
Special Considerations:
-
Patient Education and Empowerment: Educating patients about the risks and benefits of opioid therapy, promoting responsible medication use, and fostering open communication between patients and healthcare providers are crucial elements in mitigating the impact of the opioid crisis.
-
Opioid Crisis Awareness: The use of opioids, including Hydrocodone, has been the subject of intense scrutiny in recent years due to the opioid crisis. Awareness campaigns and stringent regulations aim to curb the misuse and overprescription of opioids, emphasizing the importance of responsible prescribing practices.
-
Alternative Approaches: As the medical community grapples with the challenges posed by opioid use, there is a growing emphasis on exploring alternative and multimodal approaches to pain management. Non-opioid medications, physical therapy, psychological interventions, and interventional procedures are among the strategies being considered to minimize reliance on opioids.
To conclude, Hydrocodone bitartrate is a valuable tool for healthcare providers for main management. Its ability to control moderate to severe pain has contributed to its widespread usage; however, it is not without considerations and potential risks. As the medical community continues to discover the complexities of opioid use, including heightened awareness of the opioid crisis, the responsible and informed use of Hydrocodone bitartrate remains paramount. Patient-centered care, individualized treatment plans, and a holistic approach to pain management are essential elements in achieving the delicate balance between providing relief and minimizing the risks associated with opioid therapy.
